Compounders Research Compare

Vera Therapeutics, Inc.(VERA)

Biotechnology · Brisbane, CA

$29.42-0.41 (-1.37%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Vera Therapeutics, Inc.

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.

Brisbane, CA

361 employees

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Marshall Fordyce

View full financials

Earnings Yield: N/A

Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The earnings yield is N/A as of 2026-10-06T20:43:30.110Z.

Stored calculation inputs

Calculation as of: 2026-10-06T20:43:30.110Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Unrounded diluted TTM EPS · period ending 2026-06-30: -5.86
Quote price: 29.42

FMP input reference: cf9736c803d76d66c79e1885a68840785ad6b55ce886a17ac328e1a4bc30d25a

P/E Ratio|FCF Yield|Dividend Yield|All Metrics

VERA Earnings Yield Metrics

EARNINGS YIELD

N/A

VERA Competitors' Earnings Yield

Vera Therapeutics, Inc.

Current

Market Cap

$2.11B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Addus HomeCare Corporation

Market Cap

$2.11B

Earnings Yield

5.04%

TTM Avg

4.80%

3Y Avg

4.13%

5Y Avg

3.70%

SELLAS Life Sciences Group, Inc.

Market Cap

$2.11B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GeneDx Holdings Corp.

Market Cap

$2.13B

Earnings Yield

N/A

TTM Avg

0.04%

3Y Avg

0.04%

5Y Avg

0.04%

Alvotech

Market Cap

$2.08B

Earnings Yield

N/A

TTM Avg

3.77%

3Y Avg

3.77%

5Y Avg

3.77%

Viridian Therapeutics, Inc.

Market Cap

$2.06B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Celldex Therapeutics, Inc.

Market Cap

$2.06B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Maravai LifeSciences Holdings, Inc.

Market Cap

$2.17B

Earnings Yield

N/A

TTM Avg

17.44%

3Y Avg

11.75%

5Y Avg

10.98%

Vericel Corporation

Market Cap

$2.05B

Earnings Yield

1.17%

TTM Avg

0.84%

3Y Avg

0.48%

5Y Avg

0.48%

Pharvaris N.V.

Market Cap

$2.17B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EARNINGS YIELD	TTM	3Y	5Y
Vera Therapeutics, Inc. (VERA)	$2.11B	N/A	N/A	N/A	N/A
Addus HomeCare Corporation (ADUS)vs ›	$2.11B	5.04%	4.80%	4.13%	3.70%
SELLAS Life Sciences Group, Inc. (SLS)vs ›	$2.11B	N/A	N/A	N/A	N/A
GeneDx Holdings Corp. (WGS)vs ›	$2.13B	N/A	0.04%	0.04%	0.04%
Alvotech (ALVO)vs ›	$2.08B	N/A	3.77%	3.77%	3.77%
Viridian Therapeutics, Inc. (VRDN)vs ›	$2.06B	N/A	N/A	N/A	N/A
Celldex Therapeutics, Inc. (CLDX)vs ›	$2.06B	N/A	N/A	N/A	N/A
Maravai LifeSciences Holdings, Inc. (MRVI)vs ›	$2.17B	N/A	17.44%	11.75%	10.98%
Vericel Corporation (VCEL)vs ›	$2.05B	1.17%	0.84%	0.48%	0.48%
Pharvaris N.V. (PHVS)vs ›	$2.17B	N/A	N/A	N/A	N/A

Earnings Yield vs P/E Ratio

Earnings Yield

N/A

EPS ÷ Price

P/E Ratio

N/A

Price ÷ EPS

Formula: Earnings Yield = (EPS / Price) × 100

Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.

How earnings yield is used:

It expresses earnings relative to share price as a percentage
It can be compared with FCF yield and dividend yield
It can be compared with bond yields because both are percentages
It is mathematically the inverse of the P/E ratio

Earnings Yield Formula & Definition

Earnings Yield = EPS (TTM) / Share Price

Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

P/E Ratio FCF Yield Dividend Yield All Metrics